HOSPITAL UNIVERSITARIO RUBER
Departamento
University of Edinburgh
Edimburgo, Reino UnidoPublicaciones en colaboración con investigadores/as de University of Edinburgh (8)
2024
-
Disease-free survival as a surrogate for overall survival in HR+/HER2– early breast cancer: A correlation analysis
European Journal of Cancer, Vol. 202
2023
-
Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 2998-3008
-
Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 Therapy
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 2988-2997
-
Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023
Annals of Oncology
2021
-
The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer
Breast Cancer Research and Treatment, Vol. 187, Núm. 1, pp. 155-165
-
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group
npj Breast Cancer, Vol. 7, Núm. 1
2020
2016
-
Adjuvant bisphosphonates in early breast cancer: Consensus guidance for clinical practice from a European Panel
Annals of Oncology, Vol. 27, Núm. 3, pp. 379-390